These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9172288)

  • 21. [APC resistance: pathogenesis, diagnosis, prevalence and importance of a new thrombosis risk factor].
    Wankmüller H; Schwender S; Keller F
    Med Klin (Munich); 1996 May; 91(5):308-12, 324. PubMed ID: 8709909
    [No Abstract]   [Full Text] [Related]  

  • 22. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
    Dahlbäck B
    Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic impact of the introduction of the ProC Global assay in the screening strategy of protein C pathway abnormalities in unselected patients with a history of venous thromboembolism.
    Toulon P; Adda R; Perez P
    Thromb Haemost; 2001 Aug; 86(2):720-1. PubMed ID: 11522035
    [No Abstract]   [Full Text] [Related]  

  • 24. A more discriminating test for APC resistance and a possible screening test to include protein C and protein S.
    Denson KW; Haddon ME; Reed SV; Davidson S; Littlewood TJ
    Thromb Res; 1996 Jan; 81(1):151-6. PubMed ID: 8747530
    [No Abstract]   [Full Text] [Related]  

  • 25. Anticoagulant response to activated protein C: method validation and assay comparison.
    Calkins T; Greengard J; Griffin JH; Bylund D
    J Clin Lab Anal; 1995; 9(6):418-23. PubMed ID: 8587012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sensitivity of the ProC global assay for protein C pathway abnormalities. clinical experience in 899 unselected patients with venous thromboembolism.
    Toulon P; Adda R; Perez P
    Thromb Res; 2001 Oct; 104(2):93-103. PubMed ID: 11672753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma.
    Kapiotis S; Quehenberger P; Jilma B; Handler S; Pabinger-Fasching I; Mannhalter C; Speiser W
    Am J Clin Pathol; 1996 Nov; 106(5):588-93. PubMed ID: 8929467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A protein S functional assay yields unsatisfactory results in patients with activated protein C resistance.
    Simioni P; Gavasso S; Luni S; Invidiato S; Girolami A
    Blood Coagul Fibrinolysis; 1995 May; 6(3):286-7. PubMed ID: 7654942
    [No Abstract]   [Full Text] [Related]  

  • 30. Meizothrombin: active intermediate formed during prothrombinase-catalyzed activation of prothrombin.
    Doyle MF; Haley PE
    Methods Enzymol; 1993; 222():299-312. PubMed ID: 8412800
    [No Abstract]   [Full Text] [Related]  

  • 31. Variation in test results for APC resistance with factor V deficient plasma from different donors.
    Jones MP; Carrington L; Cutting M; Alving B
    Thromb Haemost; 1997 Mar; 77(3):601. PubMed ID: 9066017
    [No Abstract]   [Full Text] [Related]  

  • 32. An improved test to identify aPC-resistant factor V-Leiden.
    Preda L; Erba N; Figini S; Carniti GC; Rossi E
    Thromb Res; 1997 Jun; 86(6):461-8. PubMed ID: 9219326
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simple procedure that increases the specificity of the activated protein C resistance test in samples containing antiphospholipid antibodies.
    Jacobsen EM; Wisløff F
    Thromb Res; 1997 Jun; 86(5):385-91. PubMed ID: 9211629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistance to activated protein C as a basis for venous thrombosis.
    Svensson PJ; Dahlbäck B
    N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The factor V R2 allele: risk of venous thromboembolism, factor V levels and resistance to activated protein C.
    Luddington R; Jackson A; Pannerselvam S; Brown K; Baglin T
    Thromb Haemost; 2000 Feb; 83(2):204-8. PubMed ID: 10739373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.
    Alshaikh NA; Rosing J; Thomassen MCLGD; Castoldi E; Simioni P; Hackeng TM
    J Thromb Haemost; 2017 May; 15(5):950-960. PubMed ID: 28211163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Familial thrombophilia due to resistance to activated protein C].
    Cuevas V; Tortosa JI; Rodríguez C; Alonso JM; García Frade LJ
    Sangre (Barc); 1994 Aug; 39(4):283-6. PubMed ID: 7985058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a new screening assay ProC Global for identification of defects in the protein C/protein S anticoagulant pathway.
    Ruzicka K; Kapiotis S; Quehenberger P; Handler S; Pabinger-Fasching I; Mannhalter C; Jilma B; Speiser W
    Thromb Res; 1997 Sep; 87(6):501-10. PubMed ID: 9330432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of the APTT- and ETP-based APC sensitivity tests.
    de Visser MC; van Hylckama Vlieg A; Tans G; Rosing J; Dahm AE; Sandset PM; Rosendaal FR; Bertina RM
    J Thromb Haemost; 2005 Jul; 3(7):1488-94. PubMed ID: 15978106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.